Spineguard (ALSGD.PA) Stock Price
Spineguard Price
Over the last 15 years Spineguard grew revenue by 2.3% annually, reaching 3.76 M EUR. For Spineguard, the net margin of -55.0% is down versus -39.2% a few years ago.
Spineguard stock price
Spineguard business model & stock analysis
Frequently asked questions about Spineguard
The business model of Spineguard SA focuses on providing innovative medical devices for spine surgery. Spineguard develops and markets tools that enhance surgical safety and accuracy during spinal procedures. The company's flagship product, DSG™ (Dynamic Surgical Guidance), is a real-time nerve detection technology that aids surgeons in avoiding potential nerve injuries. By combining cutting-edge technology with extensive medical expertise, Spineguard aims to improve patient outcomes and revolutionize spinal surgery practices. Spineguard SA's business model centers on manufacturing and commercializing these advanced surgical tools, ensuring safer and more efficient procedures for medical professionals worldwide.
Spineguard SA is primarily active in the medical technology industry.
The main competitors of Spineguard SA in the market include companies like Medtronic, NuVasive, Zimmer Biomet, and Globus Medical.
SpineGuard SA is a leading medical technology company specializing in the development and commercialization of innovative surgical solutions to make spine surgery safer and more efficient. Founded in 2009, the company is based in France and has operations globally. With a focus on real-time feedback technology, SpineGuard SA has developed a unique platform that enables surgeons to accurately and easily detect potential risks during spinal surgeries. This not only enhances patient safety but also improves surgical outcomes. SpineGuard SA has a strong commitment to research and development, constantly striving to deliver cutting-edge solutions to healthcare professionals worldwide.
Spineguard SA, a prominent medical technology company, has achieved several significant milestones. The company successfully pioneered and patented the "PediGuard" technology, a real-time nerve detection system. Spineguard's innovative system has revolutionized spine surgery by enhancing accuracy and reducing the risk of surgical complications. The company received numerous industry accolades for its groundbreaking technology, including FDA clearance and CE marking. Spineguard SA expanded its global presence by establishing partnerships with renowned medical device manufacturers. With continuous research and development, Spineguard remains dedicated to advancing spine surgery procedures and improving patient outcomes.
Spineguard SA is primarily present in various countries and regions around the world. The company's global presence extends to Europe, including France, Germany, the United Kingdom, Italy, and Spain. Additionally, Spineguard SA has a strong presence in North America, specifically in the United States and Canada. The company also operates in Asia, with a significant presence in Japan and China. With its dedication to improving spine surgery safety and innovative technologies, Spineguard SA's reach spans across multiple continents, allowing it to serve patients and healthcare professionals internationally.
Spineguard SA represents a commitment to innovation, patient safety, and improved surgical outcomes within the field of spine surgery. As a company, Spineguard focuses on developing and commercializing unique technology and products for spine surgery, offering real-time feedback and guidance to surgeons. With a strong corporate philosophy rooted in patient-centric solutions, Spineguard aims to revolutionize surgical techniques, reducing the risks associated with spinal procedures, and enhancing patient recovery. By leveraging cutting-edge technologies and expertise, Spineguard SA strives to redefine the standard of care in spine surgery, promoting the well-being and long-term outcomes for patients worldwide.
9 analysts currently rate the Spineguard stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Spineguard to generate revenue of 3.26 M EUR and earnings per share of -0.01 EUR.
The Spineguard share (ALSGD.PA) is listed on 4 stock exchanges, including: Frankfurt (6W5.F), München (6W5.MU), Paris (ALSGD.PA).
SpineGuard SA is a French company specializing in the development and sale of innovative medical devices used in surgical procedures to enhance safety and effectiveness. The company offers a range of products under two main categories: devices and services. Its device division includes the DSG® brand, which produces unique surgical instruments for skull and bone surgery. The DSG technology provides real-time information and feedback to surgeons regarding instrument positioning and the direction of planned operations, improving precision and effectiveness. In addition to skull and bone surgery, SpineGuard also offers solutions for specific spinal and neurosurgical applications. In its services division, SpineGuard provides training programs for surgeons and operating room staff to ensure optimal utilization of their DSG systems. The company also offers comprehensive financing solutions to ease the purchase and use of DSG systems for surgical facilities. SpineGuard's business model revolves around providing innovative solutions to support the field of surgery and medical institutions. By using DSG systems and other products from SpineGuard, surgeons are able to work more accurately and minimize risks, especially in challenging procedures. The investments in surgeon training and financial offerings help increase the penetration of SpineGuard's solutions and provide real support to customers in their daily practices. In summary, SpineGuard offers an innovative technology that enables better outcomes in surgery. The DSG technology is ideal for complex bone surgery and spinal issues and is supported by comprehensive training programs and financing options. The company aims to enhance patient safety and optimize medical processes to meet the demands of hospitals, doctors, and patients.
The expected revenue of Spineguard is 3.26 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Spineguard is -939,200.00 EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Spineguard is currently -8.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Spineguard stock.
The price-to-sales ratio (P/S) of Spineguard is currently 2.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Spineguard stock.
The Eulerpool Quality Score for Spineguard is 2/10.
The ISIN of Spineguard is FR0011464452. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Spineguard is A1T9RS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Spineguard is ALSGD.PA. The ticker symbol is used to trade Spineguard shares on the stock exchange.
Spineguard stock
Spineguard Peer Group
Spineguard Ticker
Spineguard FIGI
All fundamentals and in-depth analysis of Spineguard
Our stock analysis for Spineguard stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Spineguard. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.